Upper Respiratory Infections

Diagnosis

Distinguishing viral URI from bacterial sinusitis is recommended based on duration of symptoms, pattern of fever, and symptom progression, with viral URIs typically lasting 5-7 days, having an early fever, and improving after 3-6 days, as suggested by the American Academy of Pediatrics 1
Purulent nasal discharge alone is not diagnostic of bacterial infection, as nasal discharge often changes from clear to purulent and back to clear without antibiotics in uncomplicated viral URIs, according to the American Academy of Pediatrics 1
RSV diagnosis should be confirmed in high-risk patients to guide treatment and infection control, using methods such as rapid antigen detection or molecular assays, with a sensitivity of 80-90% and specificity of 90-95%, as recommended by the Infectious Diseases Society of America (IDSA) 2
The following diagnostic methods are recommended:
Diagnostic Method Sensitivity Specificity
Rapid Antigen Detection 80-90% 90-95%
Molecular Assays 90-95% 95-99%
PCR testing offers better sensitivity than rapid antigen tests for detecting respiratory viruses in older adults, with a sensitivity of 90-95% and specificity of 95-99%, as recommended by the Centers for Disease Control and Prevention (CDC) 3

Diagnostic Method	Sensitivity	Specificity
Rapid Antigen Detection	80-90%	90-95%
Molecular Assays	90-95%	95-99%

Prevention

Hand hygiene is the most effective way to prevent transmission, as recommended by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the Rhinology society, with a strength of evidence level of high 4, 5, 6

The following prevention methods are recommended:

Prevention Method	Recommendation
Hand Hygiene	Most effective way to prevent transmission, as recommended by the Rhinology society and other authorities [6, 4, 5]
Mask Use	Recommended during outbreaks, as suggested by the Rhinology society and other authorities [6, 4]
Social Distancing	Recommended during outbreaks, as suggested by the Rhinology society and other authorities [6, 4]

Palivizumab prophylaxis is recommended for high-risk infants, including premature infants ≤35 weeks gestational age and children ≤24 months with bronchopulmonary dysplasia or hemodynamically significant congenital heart disease, during RSV season, as recommended by the American Academy of Pediatrics 7, 8
Annual influenza vaccination is strongly recommended for all persons aged ≥65 years, according to the Centers for Disease Control and Prevention (CDC), with a strength of evidence level of high 9, 10
RSV vaccination is recommended for adults aged ≥60 years and people aged ≥50 years with risk factors, such as COPD, asthma, heart failure, diabetes, chronic kidney/liver disease, with a strength of evidence level of high, as recommended by the American Thoracic Society 11

Treatment

Antibiotics are ineffective for viral illnesses and should not be prescribed for uncomplicated RSV infection, as recommended by the American Academy of Pediatrics 12, 13, 14
Symptom management, including nasal saline irrigation, acetaminophen or ibuprofen, antihistamines, and oral decongestants, should be tailored to the individual patient's needs and comorbidities, with careful consideration of renal function and potential interactions, as recommended by the American Geriatrics Society (AGS) 3
First-generation antihistamine combined with decongestant (e.g., brompheniramine with pseudoephedrine) can reduce cough and other symptoms more rapidly than placebo, as recommended by the American College of Chest Physicians 15
NSAIDs like naproxen can decrease cough, headache, malaise, and myalgia in rhinovirus infections, as recommended by the American College of Chest Physicians 15
Topical decongestants can provide short-term relief, but should not be used for more than 3-5 days due to risk of rhinitis medicamentosa, as cautioned by the American College of Chest Physicians 15
Antitussives may be used for severe cough causing chest wall pain, but have limited efficacy for URI-related cough in general, with a strength of evidence level of low, as recommended by the American Geriatrics Society (AGS) 3, 14
Immunocompromised patients may require closer monitoring and more aggressive treatment for RSV infection, including combination therapy with IVIG or RSV-specific antibody preparations, as recommended by the Infectious Diseases Society of America (IDSA) 16

Infection Control

Proper hand decontamination before and after contact with patients is recommended, with alcohol-based rubs preferred (strong recommendation, evidence level B), as recommended by the American Academy of Pediatrics 17
Hand-washing with antimicrobial soap is an alternative to alcohol-based rubs, as recommended by the American Academy of Pediatrics 17
Regular cleaning of surfaces to prevent viral spread is recommended, as recommended by the American Academy of Pediatrics 17
Consider isolation or cohorting of RSV-positive patients in healthcare settings, and implement droplet precautions for children with respiratory symptoms during RSV season, as recommended by the American Academy of Pediatrics 17
In long-term care facilities, implement isolation and infection control measures during outbreaks, including antiviral prophylaxis, to prevent the spread of infection, with a strength of evidence level of high, as recommended by the Centers for Disease Control and Prevention (CDC) 3

Follow-up

Follow-up is recommended within 72 hours if symptoms worsen or fail to improve, as recommended by the Infectious Diseases Society of America (IDSA) 1
Immunocompromised patients may experience persistent infections, and require closer monitoring as they may develop more severe disease, with more aggressive management and follow-up recommended, as stated by the Infectious Diseases Society of America (IDSA) 18, 16
Elderly patients should be monitored closely for progression to lower respiratory tract infection, and return for medical evaluation if fever >38°C persists for more than 48 hours, or if breathing difficulty or worsening symptoms occur, as recommended by the American Geriatrics Society (AGS) 3
Consider the impact of comorbidities on treatment choices and outcomes, and adjust management strategies accordingly, as recommended by the American Geriatrics Society (AGS) 3